The novel atypical antipsychotic cariprazine demonstrates dopamine D(2) receptor‐dependent partial agonist actions on rat mesencephalic dopamine neuronal activity

AIM: Cariprazine, a dopamine D(3)‐preferring D(3)/D(2) receptor partial agonist, is FDA approved for the treatment of schizophrenia and acute manic or mixed episodes of bipolar disorder. This study used in vivo electrophysiological techniques in anesthetized rats to determine cariprazine's effe...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:CNS Neurosci Ther
Hlavní autoři: Delcourte, Sarah, Ashby, Charles R., Rovera, Renaud, Kiss, Béla, Adham, Nika, Farkas, Bence, Haddjeri, Nasser
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2018
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6282959/
https://ncbi.nlm.nih.gov/pubmed/29729086
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cns.12867
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky